Applied Filters
Regimen patents in Japan: LCM failures and successes
Examining a series of case studies, Takanori Abe of Abe & Partners provides an overview of lifecycle management failures and successes in regimen patents.
Is there a step between ‘inventive’ and ‘nonobviousness’?
Despite the shared language, there are tangible differences between the US, EU and UK standards, explain Jeffrey Lewis and Stuart Knight of Foley Hoag.
‘One of the most positive announcements since Brexit’: UK lawyers react to new Horizon funding deal
The news that the UK will rejoin the €95.5 billion research fund has been met with widespread relief, but it’s a bittersweet story, finds Sarah Speight. Reaction from CMS, Arnold & Porter, Bird & Bird, HGF.
Everybody loses in the end: Billion-dollar government prizes won't improve on market incentives
Bernie Sanders’ plan to ‘delink’ the price of drugs from the cost of development ignores history, argue Andrei Iancu and David Kappos.
Axonics v Medtronic: Fed Circ addresses PTAB ‘errors’
A recent precedential case highlights the thorny issue of what constitutes a fair response to new claim constructions following an institution, says Blair Jacobs of McKool Smith.
One year on: The US Inflation Reduction Act
This week marks the first anniversary of its enactment but the US Inflation Reduction Act still poses questions for pharmaceutical companies, say Alice Valder Curran and Cullen Taylor of Hogan Lovells.
UPC: life sciences lead the momentum at new court
Are we now seeing the power posed by the court as a litigation forum, asks Antje Brambrink of Finnegan.
Cannabis and IP: Nurturing innovation in Brazil’s life sciences industry
A reticent patent office and complex legal picture make getting IP protection of treatments based on the lucrative plant tricky, explain Priscila Kashiwabara and Luan Scalzitti of Kasznar Leonardos.
Life sciences trade secrets: emerging trends
With competition, employee mobility and chatbots all on the rise, protecting IP as trade secrets has never been more important for life sciences firms, says Anthony Fitzpatrick of Duane Morris.
Gilead and Teva prevail in $3.6bn antitrust trial
Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.
